- Study protocol
- Open Access
Protocol for a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of independent pharmacist prescribing in care homes: the CHIPPS study
Trials volume 21, Article number: 103 (2020)
Prescribing, monitoring and administration of medicines in care homes could be improved. Research has identified the need for one person to assume overall responsibility for the management of medicines within each care home. and shown that a pharmacist independent prescriber service is feasible in this context.
Aims and objectives
To conduct a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of a pharmacist-independent prescribing service in care homes compared to usual general practitioner (GP)-led care.
To perform a definitive randomised controlled trial (RCT) with an internal pilot to determine the intervention’s effectiveness and cost-effectiveness and enable modelling beyond the end of the trial.
This protocol is for a cluster RCT with a 3-month internal pilot to confirm that recruitment is achievable, and there are no safety concerns. The unit of randomisation is a triad comprising a pharmacist-independent prescriber (PIP) based in a GP practice with sufficient registered patients resident in one or more care homes to allow recruitment of an average of 20 participants. In the intervention group, the PIP will, in collaboration with the GP: assume responsibility for prescribing and managing residents’ medicines including medication review and pharmaceutical care planning; support systematic ordering and administration in the care home, GP practice and supplying pharmacy; train care home and GP practice staff; communicate with GP practice, care home, supplying community pharmacy and study team.
The intervention will last 6 months. The primary outcome will be resident falls at 6 months. Secondary outcomes include resident health-related quality of life, falls at 3 months, medication burden, medication appropriateness, mortality and hospitalisations. A full health economic analysis will be undertaken. The target sample size is 880 residents (440) in each arm) from 44 triads. This number is sufficient to detect a decrease in fall rate from 1.5 per individual to 1.178 (relative reduction of 21%) with 80% power and an ICC of 0.05 or less.
Recruitment is on-going and the trial should complete in early 2020. The trial results will have implications for the future management of residents in care homes and the ongoing implementation of independent pharmacist prescribing.
ISRCTN, ID: 17847169. Registered on 15 December 2017.
In 2012, UK care homes provided personal care and healthcare for almost half a million residents in registered residential or nursing care homes . Care home residents are generally frail, have multiple morbidities and are prescribed a significant number of regular medicines. Furthermore, age-related complex morbidity renders them particularly vulnerable to medication problems and errors. The Care Quality Commission identifies the management of medicines as one area of care in care homes that regularly requires review and continues to fall below the expected standards. The landmark UK-based Care Homes Use of Medicines Study (CHUMS) published in 2009  observed 256 residents in 55 care homes. Almost 70% of residents experienced at least one medication error on any given day. One hundred residents (39.1%) were identified as having one or more prescribing errors including no strength or route of medicine specified (20%), unnecessary medicine prescribed (approximately 25%), and errors in dose or strength (14.4%). Nearly a quarter of residents (57; 22.3%) experienced an administration error such as an omission (11.8%, of all errors). Out of 218 potentially harmful medicines which required biochemical monitoring, 32 (14.7%) had an error.
Many of these medication-related problems were also reported in a systematic review by Alldred et al.  which considered interventions to optimise prescribing for older people in care homes. Problems highlighted were prescription of medicines that were no longer indicated, medicines which interacted with concurrent medication, sub-optimal doses, inadequate monitoring and inappropriate duration. The inappropriate prescription of anti-psychotic medicines in care homes, and other medicines for example, benzodiazepines, non-steroidal anti-inflammatory drugs and proton-pump inhibitors, is well documented . This inappropriate prescribing is known to be related to poor quality of life, falls, strokes and increased mortality. In particular, whilst falls are multifactorial in their causation it has been noted that drugs are a modifiable risk factor and periodic drug review should be a component of any falls-reduction programme . Consequently, effective interventions are needed to monitor and discontinue inappropriate therapy.
The CHUMS report  proposed that the fundamental failing in care homes was the lack of a healthcare professional with overall continuing responsibility for medicine management, and recommended that a pharmacist should adopt this role working with a lead general practitioner (GP) within each home. The Department of Health (DH) Immediate Action Alert  arising from CHUMS required primary care organisations, GPs and community pharmacy contractors to establish effective joint working strategies to address the identified concerns. The resultant predominant model of care is that of a pharmacy team undertaking full medication reviews in care homes on a yearly or biannual basis. Two Cochrane reviews [3, 8] suggest that this model may be sub-optimal and that more effective approaches to medicine optimisation in this population are required.
Changes in United Kingdom (UK) legislation, enabling suitably trained pharmacists to prescribe, provide an opportunity for pharmacist-independent prescribers (PIPs) to assume the proposed central role in the care home environment. Evidence from the UK suggests that PIPs can prescribe safely and provide patient benefit . Recent government initiatives in all devolved UK nations have supported the deployment of pharmacists in both general practices and care homes [10,11,12,13,14]. However, to date, there is no gold-standard randomised controlled trial (RCT) evidence of the clinical or cost-effectiveness of this approach.
The aim of the study described in this protocol is to conduct a cluster RCT, with internal pilot, to compare the clinical and cost-effectiveness of a Care Homes Independent Pharmacist Prescribing Service (CHIPPS) with usual care. This is the final stage of a programme of work, divided into discrete work packages, following the Medical Research Council (MRC) guidance on the development and evaluation of complex interventions  which has reviewed the literature to select appropriate outcome measures , ascertained the views of stakeholders , developed a needs-based PIP training package (publication in preparation) and conducted a non-randomised feasibility study .
This is a cluster RCT conducted in primary care involving participating GP-PIP-care home triads in four study locations linked geographically to the Universities of East Anglia, Leeds, Aberdeen and Queen’s Belfast, (hereafter referred to by the University identity). A complete list of study sites is available from the Senior Programme Coordinator Mrs. Laura Watts; L.Watts1@uea.ac.uk.
The objectives for the cluster RCT are:
To use an embedded (internal) pilot study to confirm:
◦ the feasibility of recruiting sufficient GP practices, PIPs, care homes and residents
◦ the availability of data for primary outcome at 3 months
◦ that there are no intervention-related safety concerns
If the pilot is successful, to deliver a full RCT to:
Describe the clinical effectiveness of the intervention: PIPs assuming responsibility for medicines’ management of elderly residents in care homes
To estimate the cost-effectiveness of the intervention
The intervention will be delivered by trained PIPs for a period of 6 months. The training programme comprises 2 days of face-to-face instruction, time in practice to develop relationships with the GP and care home staff, and to address any self-assessed competency gaps supported by a mentor, and a formal final sign-off by a GP, who is independent of the research. The development and evaluation of the training programme will be published separately.
The intervention has been tested in a feasibility study . It involves the PIP, in collaboration with the care home resident’s GP, assuming responsibility for managing the medicines of the resident, including:
Reviewing resident’s medication and developing and implementing a pharmaceutical care plan
Assuming prescribing responsibilities
Supporting systematic ordering, prescribing and administration processes with each care home, GP practice and supplying pharmacy where needed
Providing training in care home and GP practice
Communicating with GP practice, care home, supplying community pharmacy and study team
Details of the intervention to be delivered by the PIP are in the CHIPPS Service Specification (Additional file 1) which was developed in previous work packages.
The study PIPs will work closely with the care home staff and the resident’s GP, and communicate regularly with both parties. Once residents are recruited, the local researcher will maintain regular contact with the PIP to ensure adherence to study procedures. During the study there will be a check of a random 20% sample of the pharmaceutical care plans and associated resident documents by a study geriatrician, to ensure clinical appropriateness and safety. Additionally, should any problem arise, the geriatrician will discuss this with the Programme (DW, RH) or Trial (CB, RH) Chief Investigator or local Principal Investigator (DA,CB, CH, DW). At the end of the study period the intervention will cease unless the GP practice and care home mutually agree to continue to deliver it outwith the framework of the research programme.
The comparator will be usual GP-led care. Whilst pharmacists may already be providing some services for care homes, these are usually annual or biannual visits and unlike the intensive approach proposed here. At the end of the study period all PIPs in the control practices will be offered access to the study training. Any medical practices which employ pharmacists to provide services to care homes of similar intensity to that which we propose will be excluded.
The inclusion and exclusion criteria for the study participants are:
Registered as a PIP with regulating body (GPhC (England and Scotland) or Pharmaceutical Society of Northern Ireland (Northern Ireland))
Following CHIPPS study training, can demonstrate to their mentor and independent GP assessor competence to deliver the service specification
Ability to work flexibly and commit a minimum of 16 h a month to deliver the service for 6 months
Substantive employment with the community pharmacy (branch/store) which supplies medicines to the care home with which the PIP would work, to protect against conflict of interest
Already providing an intensive service to the care home, e.g. a monthly visit (or more frequently), and provision of intensive medication-focussed services
The GP practice must manage sufficient care home residents to support recruitment of the target of approximately 20 eligible participantsFootnote 1
Exclusion criteria: none
Care Quality Commission (CQC) in England, Care Inspectorate in Scotland or Regulation and Quality Improvement in Northern Ireland, registered specialism as caring for adults aged over 65 years
Primarily caring for residents aged over 65 years
Associated with a participating GP practice (i.e. one or more residents registered with a participating practice)
Care homes which receive regular (e.g. a monthly visit or more frequently), from a pharmacist, providing other intensive medication-focussed services
Care homes which receive regular (e.g. a monthly visit or more frequently), from another healthcare professional, providing other intensive medication-focussed services
Care homes which are currently under formal investigation with the Care Quality Commission (CQC) in England, Care Inspectorate in Scotland or Regulation and Quality Improvement in Northern Ireland
Care homes that are participating in any other study likely to affect the outcome of the CHIPPS trial (e.g. falls intervention study, rehydration study, etc.)
Care home residents
Under the care of the participating GP practice
Aged 65 years or over
Currently prescribed at least one regular medication
They or their appropriate representative is/are able to provide informed consent/assentFootnote 2
Permanently resident in care home (not registered for respite care/temporary resident)
Currently receiving end-of-life care, (equivalent to yellow (stage C) of the Gold Standards Framework prognostic indicator) 
Have additional limitations on their residence (e.g. held securely)
Participating in another intervention research study
The study outcomes and data sources are summarised below.
Fall rate per person at 6 months as documented in the care home falls’ record
Proxy resident EQ-5D-5 L (quality of life) at baseline, 3 months and 6 months 
Face-to-face self-reported resident EQ-5D-5 L (for participants with capacity) at baseline, 3 months and 6 months 
Proxy Barthel Index (physical functioning) completed at baseline, and 6 months by identified member of care home staff 
Fall rate per person in the past 3 months at baseline, 3 months and 6 months as documented in care home records
Health-service utilisation (and associated costs) in the past 3 months at baseline and in the past 6 months at 6 months’ follow-up, collected from care home and GP records
Change in hospitalisation rate per person (baseline rate defined as 3 months prior to randomisation compared with hospitalisation rate at 6-month follow-up) collected from care home records
Drug Burden Index (DBI)  at baseline and 6 months with medication data collected from GP records
Cost-effectiveness of the PIP intervention from the perspective of the NHS and care home
In addition, in the internal pilot stage which is now completed, the following data (stop-go criteria) were collected.
Quantification of interest from medical practices-PIPs-care home(s) to confirm the viability of planned target recruitment numbers and time line
> 30% of eligible patients have been recruited (from those invited in each home)
> 80% of data are available at 3 months for falls data
No significant intervention-related safety concerns
A detailed process evaluation is being conducted following MRC guidance  and will be published separately.
Participant identification and recruitment
Recruitment and consent will be complex due to the need to identify medical practices with a PIP, recruit homes and then residents for each triad. Initially, PIPs and GPs will be recruited concurrently, with the care homes recruited subsequently, followed by the residents. Copies of recruitment documentation to be used in England and Northern Ireland are attached in Additional file 2. Scottish versions required some slight changes in terminology, to accommodate the different regulations for adults with incapacity, and are available on request.
PIP and GP recruitment
Eligible PIPs in each area will be identified using local networks, and initial informal contact will be followed by formal invitation to PIP and GP practice (letter of invitation, Participant Information Sheet, Consent Form) and consent. PIPs will be recruited, together with the GP practice with whom they should ideally have an already established close working relationship. Basic demographic information about interested GP practices and their linked care home (e.g. the resident mix, home ownership) will be collected to allow purposive sampling if numbers allow. However, if this does not provide sufficient GP practice-PIP pairings, PIPs and GP practices will be approached separately and linked before care homes are approached.
Care home recruitment
The participating GP practice will approach one (or more, if necessary) of their eligible care homes and invite them to take part in the study. If the care home manager expresses interest, they will be sent a formal invitation pack by the local researcher (including a letter and Information Sheet). If a care home declines participation, the GP will contact another home and invite them to participate. If there are insufficient residents in one home, then up to two further homes can be recruited. Where a home does not wish to participate, and there is no alternative home, a different GP practice in that area will be identified and recruited and the process to recruit the care home(s) will be repeated.
GPs will identify from their lists of registered patients, those resident in the participating care homes taking one or more medications, and screen them against the study inclusion and exclusion criteria. Reasons for any exclusions will be recorded on a standard form collected by the local researcher. Care home managers will hand out invitation packs (invitation letter from GP, Participant Information Sheet (spoken version if necessary) and consent form) directly to potential resident participants. The care home manager will visit each resident after at least 24 h, and obtain verbal consent for the local researcher to be allowed to approach them to discuss participation in the study. For residents who are considered by the manager to lack capacity, packs will be posted to the resident’s next of kin. To minimise selection bias, packs will be distributed in the order of the list of names from the GP.
The local researcher will meet with interested residents, administer the Capacity Assessment for Residents Form (see Additional file 3) and, if appropriate, take fully informed consent. For those without capacity, there are country-specific regulations to adhere to for each of the home nations; these are detailed in Table 1. The approach is in line with recommended practice .
If someone loses capacity during the 6 months of the study, they will remain in the study. This is a specific statement on the Consent Form: ‘I agree to continue participating in the study if I lose capacity before the end of the study’. If someone should lose capacity during the study, continued participation will be confirmed with the next of kin following the same procedures as for initial consent.
At each follow up visit, the care home manager will be asked if any participants have re-gained capacity. Should anyone re-gain capacity during the course of the study, and if the resident is willing, their personal consent to continue will be obtained using the template Resident Recovered Capacity documents, and in England it would be with the original Patient Information and Consent. It is made clear in the Participant Information Sheets that if residents decide not to continue, all the information collected so far will remain in the study, but no further information will be collected.
Randomisation and blinding
Randomisation will be at practice level rather than the home level in order to minimise contamination which may occur if two homes were in the same practice and one received the intervention whilst the other did not. It is not appropriate to randomise at resident level as the intervention is designed to affect medication-related processes at an institutional (care home), as well as a resident, level and, therefore, control participants would not be immune to its effects.
Blocked randomisation will be undertaken by geographical area, using a web-based electronic randomisation system integrated into the study database. The triads will be informed of their randomisation group by the Senior Programme Coordinator. Local Principal investigators at each geographical site will be informed of the allocations of their triads, (CB, DW, DA, CH) and one of the trial co-CIs (CB) will be informed of all allocations by coded emails. The GP and care homes in each triad are blinded until the care home residents have been recruited. The PIPs are unblinded once randomisation has been completed as the intervention PIPs have to complete training and competency assessment prior to the intervention start. Due to the nature of the intervention, study participants cannot be blinded to the intervention. The local researchers will be blinded until after care home residents have been recruited and baseline data collection has been completed. Should they inadvertently be unblinded they are asked to inform the Senior Programme Coordinator. As the researcher may or may not be correct in suspecting that they know the group allocation their perceived unblinding is not confirmed by the Senior Programme Coordinator until after baseline data have been collected. The potential unblinding is noted on the non-conformance report which is reviewed by the PSC and DMC. The trial statistician is advised of the triads where there is potential unblinding and will assess whether this appears to have resulted in any bias in reporting by comparison with triads where there was no reported unblinding.
Data, as specified earlier, will be collected, by the local researcher, from GP practice and care home paper and/or digital records. Data will be coded and entered into either paper Case Record Forms (CRFs) or electronically using tablets. Data entered on paper records will be subsequently entered into a centrally held Norwich Clinical Trials Unit (NCTU) CHIPPS REDCap  database by local researchers. Data collected electronically will be entered into the REDCap database at the time of data collection if there is Internet connectivity, or if working off-line, at the next time the device is synchronised. Data will be protected using established NCTU procedures.
Data management is detailed in the Data Management Plan version 1: 21 November.2017. Local research staff will receive training in all aspects of data collection and management. Identification logs, screening logs and enrolment logs will be kept at each of the four University locations in a locked cabinet within a secured room. All data will be handled in accordance with the General Data Protection Regulations 2018. All participants (GPs, care homes and residents) will be given a unique study Participant Identification Number (PIN). Data will be entered under this identification number onto the centrally held database stored on the servers based at NCTU. Access to the database will be controlled with unique usernames and encrypted passwords, and restricted to members of the CHIPPS study team, and external regulators if requested. The servers are protected by firewalls and maintained according to best practice. The physical location of the servers is protected by CCTV and security door access.
The database and associated code lists have been developed by the Study Coordinators in conjunction with NCTU. The database software (REDCap) provides a number of features to help maintain data quality, including: maintaining an audit trail, allowing custom validations on all data, allowing users to raise data-query requests, and search facilities to identify validation failure/missing data.
Once data entry is complete the database will be locked prior to any trial analysis or unblinding. The Data Management Team will provide a read-only link for the Trial Statistician to access the data. After completion of the study the database will be retained on the servers of NCTU for on-going analysis, for 10 years.
The screening and enrolment logs will remain at the care home. For recruitment monitoring purposes, identifiable patient information will be redacted, and pseudoanonymised copies of these logs being taken to the research office. Following consent, identifiable (consented participants only) screening data, linked to the Participant Identification Number, will be held locally at the University research office, in a locked filing cabinet. After completion of the study the identification, screening and enrolment logs will be securely archived at each University research office for 10 years, unless otherwise advised by NCTU.
A sample size of 880 (440 in each arm) would detect a decrease in fall rate from 1.50 per individual over 6 months to 1.178 with 80% statistical power. These assumptions are based upon data from the CAREMED  study, which found a fall rate of 1.5 per individual over a 6-month period and an intraclass correlation coefficient (ICC) no greater than 0.07 for the endpoint of interest. The detectable difference (from 1.5 to 1.178) is a relative reduction of 21% which is half that detected within a UK-based, pharmacist-led medication review service provided to care homes . The CAREMED trial indicated a mortality rate of 33% and further loss to follow-up of 5% over 12 months. Thus, a reasonable estimate of total losses due to mortality or other reasons over 6 months would be 20%, and is taken into account in the above. However, we will use data, where possible, up to the point at which someone withdraws from the study.
To recruit 880 resident participants there will be a recruitment target of 44 triads, with a mean of 20 participants from each, a loss rate of no more than 20% and an ≤ ICC of 0.05.
An intention-to-treat analysis will be conducted. The primary outcome (‘falls per resident’) will mostly likely follow a Poisson distribution and a between-group comparison to estimate the difference in falls will be made using a Poisson Regression model. This model will include baseline fall rate, prognostic variables (specified prior to analysis) and group as a fixed factor. The unit of analysis will be the individual participant but, due to the study design incorporating ‘clustering’ these unit outcomes are likely to be correlated. Therefore, a Generalised Estimation Equation (GEE) approach will be used. The Poisson assumption will be assessed with ‘fit’ statistics and, if appropriate, a Zero Inflated Poisson, or a Poisson model with an over-dispersion term will be considered. An analogue GEE model will be used for secondary outcomes, with an appropriate change to the error distribution (e.g. Normal). The estimate of the between-group difference will be provided with a 95% confidence interval and tested at the 5% significance level.
There are currently no plans for any subgroup analyses.
Safety reporting of Serious Adverse Events
The processes for the recording of SUSARs (Sudden Unexpected Serious Adverse Events), SAEs (Serious Adverse Events) and AEs (Adverse Events) and near misses in PIP documentation, GP and care home records, notification to NCTU, CI review, expedited and periodic reporting to REC will be documented in the study-specific Safety Management Plan.
For the purposes of this trial, SAEs are defined as inpatient hospitalisation and death. The expedited, i.e. immediate reporting is required if they are:
related to the study (i.e. they resulted from the intervention) and
unexpected (referred to hereafter as SUSARs)
A mixture of prospective and retrospective SUSAR notification will be used.
Prospective: from the beginning of the intervention until 30 days after the intervention ends GPs will be asked to report SUSARs immediately via a SUSAR Form to a dedicated NCTU safety email address.
Retrospective: a systematic retrospective collection of SAEs will be conducted in both intervention and control practices, whereby the NCTU Trial Manager will contact every participating care home once a month and ask about any SAEs. Deaths and hospitalisations in both arms will also be reported to the REC via the annual report.
The causality assessment of the SAE should be given by the GP. If the GP identifies a positive causality (i.e. the SAE is linked to the PIP intervention and is, therefore, a SUSAR) then this is signed off by the CI. The GP must assess the causality of all SAEs in relation to the PIP intervention using the definitions in the table below. If the event is classified as ‘serious’ and assessed as being related to the PIP intervention then a SUSAR Form must be completed and NCTU notified within 24 h.
All staff involved in the care of study participants (i.e. PIPs, care home staff, any other healthcare professionals) will also be asked to report, immediately, to a separate dedicated email address (email@example.com), any events about which they are concerned. NCTU can be notified of any further safety concerns or near misses by all staff involved in the care of study participants via a study-specific safety email address Table 2.
The trial is overseen by a Trial Management Group (TMG) comprising the Programme Chief Investigator, The Trial Co-Chief Investigators, the local Principal Investigators, the Senior Programme Manager, the NCTU Manager and the Programme Administrator. The trial is advised by a Programme Steering Committee (PSC) which provides expert oversight of the trial, making decisions as to the future continuation (or otherwise) of the trial, by monitoring recruitment rates, approving proposals by the TMG concerning any change to the design of the trial, as well as receiving letters of feedback from the independent Data Monitoring Committee (DMC). The DMC comprises a statistician, an academic pharmacist with an interest in patient safety, and an academic GP (Chair) with extensive trials’ experience. The DMC has a remit to monitor the safety of the trial participants through examination of trial safety and efficacy data, thereby providing advice to the Chair of the Programme Steering Committee (PSC). The DMC Chair informs the Chair of the PSC if, in the view of the DMC, one trial arm is clearly indicated or contraindicated (for all participants or a particular category of participants), and there is a reasonable expectation that this new evidence would materially influence patient management.
There is a study Quality Management and Monitoring Plan (version 2: 1 June.2018) which details the procedures for quality control and data monitoring by the NCTU. The study will also be subject to random monitoring by the host Universities and local Research and Development Departments.
The internal pilot study confirmed the feasibility of all study processes and no safety concerns were identified. The results will be reported in full when the main trial findings are published. Resident recruitment is ongoing and on target. The trial is expected to complete in early 2020. The TMG is grateful for the support of the TSC and DMC who have confirmed that to date there are no concerns.
The study should provide important information on the clinical and cost-effectiveness of involving pharmacists in general practices and care homes –a policy being widely rolled out across all home nations but with no RCT of evidence. The trial is part of a programme of work, part of which has been to develop a training programme for pharmacists involved in care homes and this will be made publicly available. The study also includes a detailed process evaluation and, taken together with the trial results, the findings should allow recommendations to be made about the optimum way to roll out and manage this wider role for pharmacists. At a time when the UK population is ageing, the results will be relevant both to care home residents and frail, community-dwelling older adults (Additional file 4).
Availability of data and materials
Requests for access to the final trial dataset will be considered, and approved in writing where appropriate, after formal application to the TMG/PSC. Considerations for approving access are documented in the PMG/PSC Terms of Reference.
Based on earlier work, we anticipate a consent rate of 55% and so would expect to invite approximately 35 residents/GP practice
The study will recruit residents both with and without capacity because this is representative of care home populations, where many residents are without capacity, and to exclude such residents would render the research ungeneralisable. In addition, all residents could benefit from the intervention, and so residents without capacity should not be denied the opportunity to participate
Care Homes: Care Quality Commission; 2012. Available from: http://www.cqc.org.uk/about-us/services-we-regulate/care-homes. Accessed 22 Feb 2014
Barber N, Alldred D, Raynor D, et al. The Care Homes Use of Medicines Study: prevalence, causes and potential harm of medication errors in care homes for older people. Qual Saf Healthc. 2009;18:341–6.
Alldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016;(2). Art. No.: CD009095. https://doi.org/10.1002/14651858.CD009095.pub3.
Parsons C, Johnston S, Mathie E, Baron N, Machen I, Amador S, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging. 2012;29:143–55.
de Jong MR, Van der Elst M, Hartholt KA. Drug-related falls in older patients: implicated drugs, consequences, and possible prevention strategies. Ther Adv Drug Saf. 2013;4(4):147–54. https://doi.org/10.1177/2042098613486829.
Alldred D, Barber N, Buckle P, et al. Care home use of medicines study (CHUMS). Medication errors in nursing and residential care homes – prevalence, consequences, causes and solutions. Report to the Patient Safety Research Portfolio. 2009.
Department of Health: The use of medicines in care homes for older people DH ALERT (2010) 001. 2010.
Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, Ryan C, Hughes C. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;(9). Art. No.: CD008165. https://doi.org/10.1002/14651858.CD008165.pub4.
Bruhn H, Bond C, Elliott A, Hannaford P, Lee A, McNamee P, et al. Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial. BMJ Open. 2013;3(4):e002361 doi:10.1136.
NHS England Clinical Pharmacists in General Practice https://www.england.nhs.uk/gp/gpfv/workforce/building-the-general-practice-workforce/cp-gp/. Accessed 10 July 2019.
Scottish Government Primary Care Fund – Pharmacists in GP Practices https://www2.gov.scot/Topics/Health/NHS-Workforce/Pharmacists/Pharmacy. Accessed 10 July 2019.
NHS Wales clinical pharmacists in GP practices. http://www.wales.nhs.uk/news/40188. Accessed 10 July 2019.
Health and Social Care Board Practice Based Pharmacists. http://www.hscboard.hscni.net/our-work/integrated-care/gps/investment-in-gp-practices/. Accessed 10 July 2019.
Wickware C. Government announces extra role for pharmacists in care homes as part of £3.5bn funding package. Pharm J. 2018;301:7920. https://doi.org/10.1211/PJ.2018.20205790.
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655.
Millar A, Daffu-O’Reilly A, Hughes CM, Alldred DP, Barton G, Bond CM, et al. Development of a core outcome set for effectiveness trials aimed at optimising prescribing in older adults in care homes. Trials. 2017;18:175. https://doi.org/10.1186/s13063-017-1915-6.
Bond CM, Lane K, Poland F, Maskrey V, Blyth A, Desborough JA, et al. Care Homes Independent Pharmacist Prescribing Study (CHIPPS): GP views on the potential role for pharmacist independent prescribers within care homes. Int J Pharm Pract. 2016;24(s2):6.
Inch J, Notman F, Bond C, Alldred D, Arthur A, Blyth A, Daffu-O’Reilly A, Ford J, Hughes C, Maskrey V, Millar A, Myint P, Poland F, Shepstone L, Zermansky Z, Holland R, Wright D. The Care Home Independent Prescribing Pharmacist Study (CHIPPS) – A non-randomised feasibility study of independent pharmacist prescribing in care homes. Pilot Feasibility Stud. 2019;5:89 In press.
Gold Standards Framework. http://www.goldstandardsframework.org.uk/. Accessed 10 July 2019.
Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. OHE Research Paper. London: Office of Health Economics; 2016. Available at: https://www.ohe.org/publications/valuing-health-related-quality-life-eq-5d-5l-value-set-england. Accessed 19 Dec 2019
Mahoney FI, Barthel D. Functional evaluation: the Barthel Index. Maryland State Med J. 1965;14:56–61.
Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A Drug Burden Index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–7.
Moore G, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, Moore L, O’Cathain A, Tinati T, Wight D, Baird J. Process evaluation of complex interventions: Medical Research Council guidance. BMJ. 2015;350:h1258. https://doi.org/10.1136/bmj.h1258.
NHS England Mental Capacity Act. https://www.nhs.uk/conditions/social-care-and-support-guide/making-decisions-for-someone-else/mental-capacity-act/. Accessed 10 July 2019.
Heike von Lützau-Hohlbein 2011:Ethics of dementia research http://www.alzheimer-europe.org/Ethics/Ethical-issues-in-practice/Ethics-of-dementia-research/Informed-consent-to-dementia-research Accessed July 10th 2019
Mental Welfare Commission Scotland Adults with Incapacity Act. http://www.legislation.gov.uk/asp/2000/4/section/16. Accessed 10 July 2019.
DiazOrdaz K, Slowther A, Potter R, et al. Consent processes in cluster-randomised trials in residential facilities for older adults: a systematic review of reporting practices and proposed guidelines BMJ Open. 2013;3:e003057. https://doi.org/10.1136/bmjopen-2013-003057.
Research Electronic data capture REDCap. https://www.project-redcap.org/. Accessed 10 July 2019.
Houghton J, on behalf of the CARE MED study team, Kirthisinga V, on behalf of the CARE MED study team, Desborough JA, on behalf of the CARE MED study team. Multi-professional medication reviews in care homes for older people: results from the CARE MED randomised controlled trial. Age Ageing. 2014;43(suppl_2):ii19–20 10.1093/ageing/afu131.5.
Zermansky AG, Aldred DP, Petty DR, et al. Clinical medication review by a pharmacist of elderly people living in care homes-randomised controlled trial. Age Ageing. 2006;35:586–91.
We also thank the members of the research team who have contributed, or are contributing, daily to deliver the RCT (University of East Anglia: Laura Watts, Joanna Williams, Bronwen Harry, Jeanette Blacklock, Caroline Hill, Frances Johnston; University of Aberdeen: Jacqueline Inch, Frances Notman, Lindsey Dalgarno; University of Leeds: Amrit Daffu O’Reilly; Queens University Belfast: Anna Millar, Maureen Spargo, Mairead McGrattan); PPIRes (Public and Patient Involvement in Research) for being formal collaborators on the grant and for advice on ongoing conduct of the study as represented by Kate Massey (sadly deceased) and Christine Handford. We thank Ian Small, lead primary care medicines management pharmacist in Norwich (now retired) and a co-applicant on the NIHR programme grant. On behalf of the CHIPPS Team, we would also like to acknowledge the NHS South Norfolk Clinical Commissioning Group (CCG) as the study sponsor and host of PPIRes and, especially, Clare Symms, Norfolk and Suffolk Primary and Community Care Research Office for her contribution towards management of the study budget. The research is also supported by the NIHR Yorkshire and Humber Patient Safety Translational Research Centre.
The Study Sponsor is South Norfolk Clinical Commissioning Group NHS with responsibility for the management of the CHIPPS trial delegated to the Trial Co-Chief Investigators and Norwich Clinical trials Unit. The contact is Clare Symms, Research Management and Finance Lead,
Norfolk and Suffolk Primary and Community Care Research Office, hosted by South Norfolk CCG.
Lakeside 400, Old Chapel Way, Broadland Business Park, Thorpe St Andrew, Norwich, NR7 0WG.
Switchboard: 01603 257000
Direct dial: 01603 257020
Mobile: 07919 302542
Generic mailbox: snccg.RandDoffice@nhs.net
Trial results will be communicated to participants, other healthcare professionals, the public, and other relevant groups via local dissemination events, briefing papers, publications in academic and professional journals, conference presentations and other invited speaker events. The PPI representatives will be especially involved in advising on dissemination to the residents, relatives and care home stakeholders, and the wider public. The main trial results will be reported on the study website (https://www.uea.ac.uk/chipps) and via Social media; e.g. the study Twitter account (@CHIPPS_Study).
This study is funded by the National Institute for Health Research (NIHR) (Programme Grants for Applied Research (Grant Reference Number RP-PG-0613-20007)). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Other than receiving routine monitoring reports, the funders have had no further involvement in the design and conduct of the trial nor any input to this paper. A copy of the paper has been sent to them for information.
Ethics approval and consent to participate
The study has been approved by both the East of England Research Ethics Committee (REC) and the Scottish REC. Approval in both countries was required because of differences in national laws for involving subjects lacking capacity to consent. Research and Development approvals have also been secured as necessary for all NHS organisational units involved. All subsequent amendments are submitted as necessary to the relevant committee and not enacted until approval has been awarded. All participants were formally invited and consented in line with the processes described in the paper.
Consent for publication
No individual person’s data in any form is included in the paper, or will be reported in the publication of the main trial results.
None of the investigators, grant holders or any of the research team members have any financial or competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bond, C.M., Holland, R., Alldred, D.P. et al. Protocol for a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of independent pharmacist prescribing in care homes: the CHIPPS study. Trials 21, 103 (2020). https://doi.org/10.1186/s13063-019-3827-0
- Older people
- Pharmacist prescribing
- Care homes
- Randomised controlled trial